Vertex and CRISPR Therapeutics secure full approval for the first gene-editing therapy to enter mainstream clinical use.
The U.S. Food and Drug Administration has approved Exa-Cel, a CRISPR-Cas9-based therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics, for patients with severe sickle cell disease. The approval marks a milestone for precision medicine—moving gene editing from experimental labs into standard care.
Exa-Cel works by modifying a patient’s hematopoietic stem cells to reactivate fetal hemoglobin production, reducing the sickling of red blood cells. Clinical trials showed 93% of treated patients remained free of vaso-occlusive crises for over 12 months post-treatment. The therapy will be priced at $2.4 million, but Vertex announced partnerships with federal programs and insurers to expand access.
Ethicists call this a watershed for human gene therapy: proof that CRISPR can deliver safe, durable outcomes. Regulators now face the challenge of scaling access while ensuring long-term monitoring. For thousands living with the disease, this approval represents hope—and the beginning of a new genomic era.